A phase 1 trial, LUMINA, is currently underway and is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in approximately 48 patients with ALS.

The FDA has granted fast track designation to Amylyx's experimental therapy AMX0114 for the treatment of amyotrophic lateral ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide that targets a specific driver of ...

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) said on Tuesday that the U.S. FDA has granted fast track status to its antisense RNA, ...

Department of Biochemistry, Queen’s University, Kingston, Ontario, Canada K7L 3N6, and Service and Department of Medical Genetics, Centre Hospitalier Universitaire Vaudois, CHUV, and Faculty of ...